Wegovy vs Mounjaro: The Real Dosing Difference Explained
Why Wegovy and Mounjaro Doses Cannot Be Directly Compared
The question of why Wegovy's dose appears lower than Mounjaro's stems from a fundamental misunderstanding about these prescription-only medicines. Wegovy contains semaglutide, whilst Mounjaro contains tirzepatide - these are completely different molecular compounds with distinct mechanisms of action. Comparing their doses is like comparing millilitres of water to grams of flour - the units represent entirely different substances with different potencies and receptor targets.
Wegovy works as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones to reduce appetite and promote satiety. Mounjaro functions as a dual agonist, targeting both GIP and GLP-1 receptors simultaneously. The maximum maintenance dose of Wegovy is 2.4mg weekly, whilst Mounjaro reaches 15mg weekly, but these numbers reflect the different molecular weights and binding affinities of semaglutide versus tirzepatide respectively.
UK's Best Wegovy Pricing: Complete Cost Breakdown
At EverydayMeds, we offer the UK's most transparent Wegovy pricing structure, starting from £79.99 for the 0.25mg starter dose. Our pricing includes your clinical assessment, prescriber review, and next-day delivery - no hidden consultation fees that other providers often add. New customers can use code FIRST40 at checkout, whilst returning customers benefit from code DOSE25 to access these competitive rates.
Our complete Wegovy pricing spans the full dose escalation journey: 0.25mg starter pens at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose (£209.99). For those seeking convenience and supply continuity, our bundle options like the Intro Trio (£299.99 for three ascending doses) provide comprehensive coverage without the worry of running out during critical dose transitions.
Clinical Evidence: Understanding Wegovy's Dosing Science
The STEP clinical trial programme, published by Wilding et al. in the New England Journal of Medicine (2021), demonstrated that Wegovy's 2.4mg maintenance dose achieved clinically significant weight management outcomes when used alongside lifestyle interventions. The dose escalation protocol used in these trials - starting at 0.25mg and increasing monthly - was specifically designed to optimise tolerability whilst building therapeutic efficacy.
This graduated dosing approach allows patients to adapt to semaglutide's effects on gastric emptying and satiety signalling, reducing the likelihood of gastrointestinal side effects that might occur with higher initial doses. The question of why Wegovy's dose appears lower than Mounjaro becomes irrelevant when considering that each medication's dosing was independently optimised through separate clinical development programmes targeting different receptor mechanisms.
How Wegovy's GLP-1 Mechanism Determines Optimal Dosing
Wegovy functions by binding to GLP-1 receptors in your brain's appetite control centres, pancreas, and digestive system, mimicking the action of your body's natural incretin hormones. This binding triggers a cascade of effects including delayed gastric emptying, enhanced insulin sensitivity when glucose levels are elevated, and direct appetite suppression through hypothalamic pathways. The 2.4mg weekly dose represents the optimal balance between therapeutic efficacy and tolerability for semaglutide's specific molecular structure and receptor binding profile. Unlike Mounjaro's dual-receptor approach requiring higher milligram amounts due to tirzepatide's different pharmacokinetic properties, Wegovy's focused GLP-1 action achieves weight management benefits at lower absolute doses whilst maintaining the same clinical significance.
Seamless Wegovy Ordering Process at EverydayMeds
Our streamlined ordering process begins with a comprehensive 3-minute clinical assessment covering your medical history, current medications, and weight management goals - essential for any prescription-only medicine. Following submission, our qualified prescribers review your assessment within 3 working days (or 24 hours with our express service), ensuring clinical appropriateness for Wegovy therapy. Once approved, your medication ships via next-day delivery using specialist cold-chain logistics to maintain the 2-8°C storage requirements. Our GPhC-registered pharmacy (#9012878) handles every aspect from clinical review to delivery, providing complete transparency throughout your treatment journey. You'll receive tracking information, storage instructions, and ongoing support to ensure optimal treatment outcomes alongside your reduced-calorie diet and increased physical activity programme.
Storage Advantages: Wegovy's Practical Benefits Over Mounjaro
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, versus Mounjaro's 21-day room temperature limit. This storage advantage makes Wegovy particularly suitable for frequent travellers or those with limited refrigerator space, reducing the anxiety around medication storage compliance. The FlexTouch pen design provides precise dose delivery with clear dose escalation markings, progressing from the initial 0.25mg through to the 2.4mg maintenance dose over 16 weeks. Each pen contains four doses, perfectly aligned with the monthly dose escalation schedule that distinguishes Wegovy's patient-friendly protocol. The combination of extended room temperature stability and intuitive pen design addresses practical concerns that often influence medication adherence in long-term weight management programmes.
Why Lower Dosing Makes Wegovy More Cost-Effective for UK Patients
The perceived "lower" dosing of Wegovy actually represents superior value when analysed on a cost-per-therapeutic-effect basis rather than simple milligram comparison. Since Wegovy achieves clinically meaningful weight management at 2.4mg weekly, patients avoid the higher absolute medication costs associated with treatments requiring larger doses to achieve similar outcomes. Our pricing structure at EverydayMeds reflects this efficiency, with the 2.4mg maintenance dose priced at £209.99 including all clinical services and delivery.
For UK patients managing long-term treatment costs, Wegovy's lower absolute dosing translates to more predictable monthly expenses compared to higher-dose alternatives that may require more expensive manufacturing processes. The question of why Wegovy's dose appears lower than Mounjaro becomes a financial advantage when you consider that lower doses mean lower production costs, savings we pass directly to patients through our competitive UK pricing structure.
Expert Prescription Support: Choosing Between Wegovy and Mounjaro
Both Wegovy and Mounjaro are available from EverydayMeds, allowing our prescribers to recommend the most suitable option based on your individual clinical profile and treatment goals. The decision between these prescription-only medicines should never be based solely on dose comparisons, but rather on factors including your medical history, tolerance profile, and lifestyle considerations such as storage requirements. Our clinical team evaluates multiple factors including previous GLP-1 experience, concurrent medications, and specific weight management objectives to guide treatment selection. During your clinical assessment, we'll discuss why Wegovy's lower dosing might actually represent the optimal starting point for your weight management journey, particularly if you're new to incretin-based therapies. Whether you proceed with Wegovy or Mounjaro, our comprehensive support ensures you receive expert guidance throughout your treatment, with the flexibility to adjust your therapy as needed under proper medical supervision.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
